A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients

Overview of attention for article published in Frontiers in oncology, May 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 16,578 followers.

#PubSalud Murcia A new prognostic model including immune biomarkers, genomic proliferation tumor markers ( AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients @Area6VegaMEdia https://t.co/WolomTaG5

16 Jun 2023

Reply Repost Favourite

New research: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients: Background Up to 30% of… #oncology https:

08 Jun 2023

Reply Repost Favourite

RT @LuengoGil: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (#AURKA and #MYBL2) and clinical-pat…

31 May 2023

Reply Repost Favourite

A new prognostic model including immune biomarkers, genomic proliferation tumor markers (#AURKA and #MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant #breast #cancer patients @IMIB_RMurcia @FFIS_CARM @UCAM_Investiga https://t.

30 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.